Molecular Basis of Loss Aversion
- Conditions
- Healthy
- Interventions
- Drug: single-dose madopar, single-dose placebo, and single-dose propranolol by orderDrug: single-dose propranolol, single-dose madopar, and single-dose placebo by orderDrug: single-dose propranolol, single-dose placebo, and single-dose madopar by orderDrug: single-dose placebo, single-dose propranolol, and single-dose madopar by orderDrug: single-dose madopar, single-dose propranolol, and single-dose placebo by orderDrug: single-dose placebo, single-dose madopar, and single-dose propranolol by order
- Registration Number
- NCT06034158
- Lead Sponsor
- Sir Run Run Shaw Hospital
- Brief Summary
The goal of this clinical trial is to test the roles of dopamine and norepinephrine in decision making related to loss aversion in the healthy population. The main question it aims to answer is whether temporarily boosting dopamine activity or temporarily suppressing norepinephrine activity has an impact on processing of potential gains and losses in financial decision making, social decision making, transaction decision making and moral decision making. Accordingly, participants will complete four decision-making tasks, namely investment task, driving task, trading task, and die task, after taking madopar, propranolol or placebo. Participants' psychological traits and psychiatric symptoms will be assessed once they are enrolled before the first-session day.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 60
- Age 25-40 years old (including boundary value).
- Elementary school education or above, able to understand the research content.
- Body temperature, blood pressure, heart rate, respiratory rate, and electrocardiogram are all normal. Among them, the blood pressure range is 100-139/70-89 mmHg, and the heart rate range is 60-85 beats/min.
- Vulnerable groups, including people with mental illness, cognitive impairment, critically ill subjects, minors, pregnant women, illiterates, etc.
- Family history of genetic diseases.
- Major physical diseases, including cardiovascular, respiratory, digestive, renal, endocrine, blood and other systemic diseases.
- History of alcohol/drug dependence.
- Lactating women.
- The cardiopulmonary function test results are poor.
- Have ever taken madopar or propranolol for medical use.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- CROSSOVER
- Arm && Interventions
Group Intervention Description madopar-placebo-propranolol single-dose madopar, single-dose placebo, and single-dose propranolol by order In a within-subjects design, participants will take madopar, placebo, and propranolol each once in three separate sessions. propranolol-madopar-placebo single-dose propranolol, single-dose madopar, and single-dose placebo by order In a within-subjects design, participants will take propranolol, madopar, and placebo each once in three separate sessions. propranolol-placebo-madopar single-dose propranolol, single-dose placebo, and single-dose madopar by order In a within-subjects design, participants will take propranolol, placebo, and madopar each once in three separate sessions. placebo-propranolol-madopar single-dose placebo, single-dose propranolol, and single-dose madopar by order In a within-subjects design, participants will take placebo, propranolol, and madopar each once in three separate sessions. madopar-propranolol-placebo single-dose madopar, single-dose propranolol, and single-dose placebo by order In a within-subjects design, participants will take madopar, propranolol, and placebo each once in three separate sessions. placebo-madopar-propranolol single-dose placebo, single-dose madopar, and single-dose propranolol by order In a within-subjects design, participants will take placebo, madopar, and propranolol each once in three separate sessions.
- Primary Outcome Measures
Name Time Method Choices to invest or not in the investment task between 1-2 hours after taking the drugs or the placebo Participants decide whether or not to accept investment options that entail a 50/50 chance of winning some amount of money and losing some amount of money.
Response times to invest or not in the investment task between 1-2 hours after taking the drugs or the placebo Participants decide whether or not to accept investment options that entail a 50/50 chance of winning some amount of money and losing some amount of money.
Response times to turn or not in the driving task between 1-2 hours after taking the drugs or the placebo Participants decide whether or not to make turns during driving in order to sacrifice some number of person(s) to save some number of person(s) .
Choices to turn or not in the driving task between 1-2 hours after taking the drugs or the placebo Participants decide whether or not to make turns during driving in order to sacrifice some number of person(s) to save some number of person(s) .
Reported outcomes in die task between 1-2 hours after taking the drugs or the placebo Participants report the outcome for each throw of the die.
Choices to buy or sell in the trading task between 1-2 hours after taking the drugs or the placebo Participants decide whether or not to buy or sell a product at certain prices.
Response times to buy or sell in the trading task between 1-2 hours after taking the drugs or the placebo Participants decide whether or not to buy or sell a product at certain prices.
- Secondary Outcome Measures
Name Time Method Affects before and 1 hour after taking the drugs or the placebo Participants' affects will be assessed using the Positive and Negative Affective Scale (PANAS).Scores can range from 10 to 50 for both the Positive and Negative Affect, with the lower scores representing lower levels of Positive/Negative Affect and higher scores representing higher levels of Positive/Negative Affect.
Trial Locations
- Locations (1)
Sir Run Run Shaw Hospital
🇨🇳Hangzhou, Zhejiang, China